According to Lepu Medical's announcement, Shanghai Minwei Biotech, a holding subsidiary of the company, has obtained a notice from the US FDA to agree to conduct clinical trials with MWN110 injections. The drug is a monoclonal antibody targeting ActRIIA/b. The application is for overweight or obesity. It has global intellectual property rights, and was approved for clinical trials by CDE in July 2026. Non-clinical studies have shown that the drug alone can significantly reduce body fat percentage, body weight, and increase muscle mass, and use in combination with simeglutide can inhibit muscle loss. Currently, no similar drugs have been approved for marketing at home or abroad.

According to Lepu Medical's announcement, Shanghai Minwei Biotech, a holding subsidiary of the company, has obtained a notice from the US FDA to agree to conduct clinical trials with MWN110 injections. The drug is a monoclonal antibody targeting ActRIIA/b. The application is for overweight or obesity. It has global intellectual property rights, and was approved for clinical trials by CDE in July 2026. Non-clinical studies have shown that the drug alone can significantly reduce body fat percentage, body weight, and increase muscle mass, and use in combination with simeglutide can inhibit muscle loss. Currently, no similar drugs have been approved for marketing at home or abroad.